Literature DB >> 22581167

Coronary stent choice in patients with acute myocardial infarction.

Giulio G Stefanini1, Stephan Windecker.   

Abstract

A prompt reperfusion with primary percutaneous coronary intervention represents the current gold standard treatment for patients with acute myocardial infarction. In this setting, coronary stents have been shown to improve outcomes compared to plain angioplasty and are routinely used. However, the stent selection among patients with acute myocardial infarction is still a matter of some debate. An increased risk of very late (>1-year) stent thrombosis has been associated with the use of early-generation drug-eluting stents (DES), leading to concerns regarding the long-term safety of these devices. Newer-generation DES were developed with the aim of addressing this safety issue, and were recently investigated in a few randomized studies in patients with acute myocardial infarction. The objective of the present review is to summarize the accumulated evidence, to guide the stent selection in patients with acute myocardial infarction.

Entities:  

Mesh：

Year:  2012        PMID： 22581167     DOI： 10.1007/s11886-012-0281-y

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  39 in total

1.  Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.

Authors:  Patrick W Serruys; Sigmund Silber; Scot Garg; Robert Jan van Geuns; Gert Richardt; Pawel E Buszman; Henning Kelbaek; Adrianus Johannes van Boven; Sjoerd H Hofma; Axel Linke; Volker Klauss; William Wijns; Carlos Macaya; Philippe Garot; Carlo DiMario; Ganesh Manoharan; Ran Kornowski; Thomas Ischinger; Antonio Bartorelli; Jacintha Ronden; Marco Bressers; Pierre Gobbens; Manuela Negoita; Frank van Leeuwen; Stephan Windecker
Journal:  N Engl J Med       Date:  2010-06-16       Impact factor: 91.245

2.  Sirolimus-eluting versus uncoated stents in acute myocardial infarction.

Authors:  Christian Spaulding; Patrick Henry; Emmanuel Teiger; Kevin Beatt; Ezio Bramucci; Didier Carrié; Michel S Slama; Bela Merkely; Andrejs Erglis; Massimo Margheri; Olivier Varenne; Ana Cebrian; Hans-Peter Stoll; David B Snead; Christoph Bode
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

3.  Drug-eluting coronary stents--promise and uncertainty.

Authors:  Gregory D Curfman; Stephen Morrissey; John A Jarcho; Jeffrey M Drazen
Journal:  N Engl J Med       Date:  2007-02-12       Impact factor: 91.245

4.  Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.

Authors:  Cheol Whan Lee; Duk-Woo Park; Seung-Hwan Lee; Young-Hak Kim; Myeong-Ki Hong; Jae-Joong Kim; Seong-Wook Park; Sung-Cheol Yun; In-Whan Seong; Jae-Hwan Lee; Nae-Hee Lee; Yoon Haeng Cho; Sang-Sig Cheong; Do-Sun Lim; Joo-Young Yang; Sang-Gon Lee; Kee-Sik Kim; Junghan Yoon; Myung-Ho Jeong; Ki Bae Seung; Taeg Jong Hong; Seung-Jung Park
Journal:  Am J Cardiol       Date:  2009-09-26       Impact factor: 2.778

5.  Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis.

Authors:  Stéphane Cook; Elena Ladich; Gaku Nakazawa; Parham Eshtehardi; Michel Neidhart; Rolf Vogel; Mario Togni; Peter Wenaweser; Michael Billinger; Christian Seiler; Steffen Gay; Bernhard Meier; Werner J Pichler; Peter Jüni; Renu Virmani; Stephan Windecker
Journal:  Circulation       Date:  2009-07-20       Impact factor: 29.690

6.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

Review 7.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

8.  Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.

Authors:  Marco Valgimigli; Gianluca Campo; Gianfranco Percoco; Leonardo Bolognese; Corrado Vassanelli; Salvatore Colangelo; Nicoletta de Cesare; Alfredo E Rodriguez; Maurizio Ferrario; Raul Moreno; Tommaso Piva; Imad Sheiban; Giampaolo Pasquetto; Francesco Prati; Marco S Nazzaro; Giovanni Parrinello; Roberto Ferrari
Journal:  JAMA       Date:  2008-03-30       Impact factor: 56.272

9.  Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty.

Authors:  Luis-S Díaz de la Llera; Sara Ballesteros; Jaime Nevado; Mónica Fernández; Manuel Villa; Angel Sánchez; Gabriel Retegui; Dolores García; Angel Martínez
Journal:  Am Heart J       Date:  2007-07       Impact factor: 4.749

10.  Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study.

Authors:  Bas L van der Hoeven; Su-San Liem; J Wouter Jukema; Navin Suraphakdee; Hein Putter; Jouke Dijkstra; Douwe E Atsma; Marianne Bootsma; Katja Zeppenfeld; Pranobe V Oemrawsingh; Ernst E van der Wall; Martin J Schalij
Journal:  J Am Coll Cardiol       Date:  2008-02-12       Impact factor: 24.094
View more
  1 in total

1.  Direct intercellular communications dominate the interaction between adipose-derived MSCs and myofibroblasts against cardiac fibrosis.

Authors:  Xiaokang Li; Hui Zhao; Chunxiao Qi; Yang Zeng; Feng Xu; Yanan Du
Journal:  Protein Cell       Date:  2015-08-14       Impact factor: 14.870
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.